Clinical trials: Macular Disease
Age-related Macular Degeneration
Vision Improvement for Patients With Age-Related Macular Degeneration
The purpose of this study is to determine whether the Optimal Acuity Clear-K® Low Vision Aid System provides a safe and effective treatment to improve vision for patients with age-related macular degeneration.
- Trial name
- AMD (NCT04268836)
- Testing
- Optimal Acuity Clear-K® Low Vision Aid System treatment
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Geographic Atrophy Due to Age-Related Macular Degeneration
A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy
This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to…
- Trial name
- NCT07668804
- Testing
- TO-O-1007 (low-dose), TO-O-1007 (high-dose)
- Where
- 3 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Theratocular Biotek Co.
Macular Edema
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
- Trial name
- DRAKO (NCT02850263)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Bayer
Macular Edema
A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)
This study will evaluate the treatment effect of three doses of the I-vation TA implant (MK0140) in diabetic patients with clinically significant macular edema.
- Trial name
- NCT00692614
- Testing
- triamcinolone acetonide
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Macular Degeneration, Choroidal Neovascularization
Phase II/III Study of Anti-VEGF in Neovascular AMD
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
- Trial name
- NCT00021736
- Testing
- EYE001 anti-VEGF aptamer
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals
Geographic Atrophy, Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
- Trial name
- NCT02130531
- Testing
- Emixustat HCl Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kubota Vision Inc.
Geographic Atrophy
Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- NCT04014777
- Testing
- NGM621
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Branch Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with…
- Trial name
- BRIGHTER (NCT01599650)
- Testing
- Ranibizumab, Laser
- Where
- 82 sites in Australia, Canada and 15 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Stargardt Disease
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Stargardt disease 1 (STGD1) is the most prevalent form of juvenile macular degeneration. It is caused by a rare, inherited autosomal recessive trait, leading to severe and irreversible blindness by the first or second decade of…
- Trial name
- NCT05266014
- Testing
- tinlarebant
- Where
- 3 sites in Australia, Taiwan
- Volunteers
- 13 people
- Sponsor
- RBP4 Pty Ltd
Macular Degeneration, Geographic Atrophy
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying…
- Conditions
- Macular Degeneration, Geographic Atrophy, Stargardt Disease
- Trial name
- NCT06805474
- Testing
- Observational
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nanoscope Therapeutics Inc.
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Retinal Drusen, Age-related Macular Degeneration
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD.
- Conditions
- Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
- Trial name
- AMD (NCT03946085)
- Testing
- Lumega-Z, AREDS2
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Guardion Health Sciences, Inc.
Age-Related Macular Degeneration
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab.
- Trial name
- NCT00607750
- Testing
- ATG003 (mecamylamine)
- Volunteers
- 60 people
- Sponsor
- CoMentis
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there…
- Trial name
- NCT01682382
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Stargardt Disease
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
- Trial name
- SUSTAIN (NCT06048185)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals